Menu
Not yet recruiting NCT06594042

Serum Preptin Level and Its Relationship With Bone Mineral Disease in Chronic Kidney Disease Patients

— Observational Preptin

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: serum preptin.
Who it may be relevant to
Registry conditions: Preptin. Basic parameters: 18 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Aim of the research:To identify preptin level and relationship with bone disease in chronic kidney disease patients.

Detailed description

Preptin is a 34-aminoacid peptide derived from the E-peptide of pro-insulin-like growth factor 2 (pro-IGF2) that is co-secreted with insulin and upregulates glucose-mediated insulin secretion. High serum preptin levels were described in conditions associated with insulin resistance, such as polycystic ovary syndrome and type 2 diabetes mellitus (T2M). Insulin and also IGF2 are known to be anabolic bone hormones .

Preptin stimulates osteoblastic proliferation and increases mineralization in a concentration-independent manner in osteoblast precursor cell , Despite being associated with insulin resistance, an increased fat mass has beneficial bone effects . While the increased mechanical loading favors bone formation, adipokines and also pancreatic and gut hormones were also proposed to mediate the relationship between fat and bone. The importance of nutritional hormones in maintaining bone mass was, thus, recognized. Insulin has anabolic bone effects, and hyperinsulinemia contributes to increased bone mineral density (BMD). Similar to insulin, insulin-like growth factor 1 (IGF1) and IGF2, preptin was recently proposed to have anabolic bone activity .

End-stage renal disease (ESRD) patients present with specific bone and mineral metabolism disturbances. Chronic kidney disease-associated mineral and bone disorder accounts for increased morbidity and mortality in those patients. Biochemical markers known thus far do not effectively predict the complex bone changes that are observed in ESRD patients .

Interventions

  • Diagnostic test serum preptin
    serum preptin level in chronic kidney disease

Primary outcome measures

  • Serum Preptin level and its relationship with bone mineral disease in chronic kidney disease patients [Time frame: baseline]

Eligibility criteria

Inclusion criteria

  • both sex groups of patients with age between 18-50 years . pre end stage renal disease and end stage renal disease patients .

Exclusion criteria

  • type 2 diabetic patients

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Case-control

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Kaluzna M, Pawlaczyk K, Schwermer K, Hoppe K, Yusuf Ibrahim A, Czlapka-Matyasik M, Wrotkowska E, Ziemnicka K, Oko A, Ruchala M. Is Preptin a New Bone Metabolism Parameter in Hemodialysis Patients? Life (Basel). 2021 Apr 12;11(4):341. doi: 10.3390/life11040341. PMID 33921361
  • Livingstone C, Borai A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin Endocrinol (Oxf). 2014 Jun;80(6):773-81. doi: 10.1111/cen.12446. Epub 2014 Mar 24. PMID 24593700
  • Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002 Nov 15;277(46):44005-12. doi: 10.1074/jbc.M208265200. Epub 2002 Sep 4. PMID 12215457
  • Naot D, Cornish J. Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone. Front Endocrinol (Lausanne). 2014 May 9;5:70. doi: 10.3389/fendo.2014.00070. eCollection 2014. PMID 24847313
  • Reid IR. Fat and bone. Arch Biochem Biophys. 2010 Nov 1;503(1):20-7. doi: 10.1016/j.abb.2010.06.027. Epub 2010 Jul 3. PMID 20599663
  • Xiao C, Li W, Lu T, Wang J, Han J. Preptin promotes proliferation and osteogenesis of MC3T3-E1 cells by upregulating beta-catenin expression. IUBMB Life. 2019 Jul;71(7):854-862. doi: 10.1002/iub.2016. Epub 2019 Feb 6. PMID 30729647
  • Ungureanu MC, Bilha SC, Hogas M, Velicescu C, Leustean L, Teodoriu LC, Preda C. Preptin: A New Bone Metabolic Parameter? Metabolites. 2023 Sep 4;13(9):991. doi: 10.3390/metabo13090991. PMID 37755271

Identifiers

NCT: NCT06594042 · preptin chronic kidney disease

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗